• 1
    Disis ML, Wallace DR, Gooley TA et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 2009; 27:46854692.
  • 2
    Benavides LC, Sears AK, Gates JD et al. Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines. Exp Rev Vaccines 2011; 10:201210.
  • 3
    Clive KS, Tyler JA, Clifton GT et al. The GP2 peptide: a HER2/neu-based breast cancer vaccine. J Surg Oncol 2012; 105:452458.
  • 4
    Coronella-Wood JA, Hersh EM. Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother 2003; 52:715738.
  • 5
    Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat 2000; 62:245252.
  • 6
    Pandey JP, Namboodiri AM, Kurtenkov O, Nietert PJ. Genetic regulation of antibody responses to human epidermal growth factor receptor 2 (HER-2) in breast cancer. Hum Immunol 2010; 71:11241127.
  • 7
    Grubb R. Advances in human immunoglobulin allotypes. Exp Clin Immunogenet 1995; 12:191197.
  • 8
    Dugoujon JM, Hazout S, Loirat F, Mourrieras B, Crouau-Roy B, Sanchez-Mazas A. GM haplotype diversity of 82 populations over the world suggests a centrifugal model of human migrations. Am J Phys Anthropol 2004; 125:175192.
  • 9
    Musolino A, Naldi N, Bortesi B et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26:17891796.
  • 10
    Namboodiri AM, Pandey JP. Differential inhibition of trastuzumab and cetuximab induced cytotoxicity of cancer cells by IgG1 expressing different GM allotypes. Clin Exp Immunol 2011; 166:361365.
  • 11
    Iwasaki M, Shimada N, Kasuga Y et al. Fragment c gamma receptor gene polymorphisms and breast cancer risk in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians. Breast Cancer Res Treat 2011; 126:497505.
  • 12
    Brusco A, de Lange GG, Boccazzi C, Carbonara AO. Molecular characterization of G2m(n+) and G2m(n–) allotypes. Immunogenetics 1995; 42:414417.
  • 13
    Balbín M, Grubb A, de Lange GG, Grubb R. DNA sequences specific for Caucasian G3m(b) and allotypes: allotyping at the genomic level. Immunogenetics 1994; 39:187193.
  • 14
    Sarvas H, Rautonen N, Käyhty H, Kallio M, Mäkelä O. Effect of Gm allotypes on IgG2 antibody responses and IgG2 concentrations in children and adults. Int Immunol 1990; 2:317322.
  • 15
    Pandey JP, Prohászka Z, Veres A, Füst G, Hurme M. Epistatic effects of genes encoding immunoglobulin GM allotypes and interleukin-6 on the production of autoantibodies to 60- and 65-kDa heat-shock proteins. Genes Immun 2004; 5:6871.
  • 16
    Pandey JP. Comment on ‘Flagellin as an adjuvant: cellular mechanisms and potential’. J Immunol 2011; 186:1299.